See more : HDC Hyundai Development Company (294870.KS) Income Statement Analysis – Financial Results
Complete financial analysis of AgeX Therapeutics, Inc. (AGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AgeX Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- CNGR Advanced Material Co.,Ltd. (300919.SZ) Income Statement Analysis – Financial Results
- Vulcan Steel Limited (VSL.AX) Income Statement Analysis – Financial Results
- Avecho Biotechnology Limited (AVEFF) Income Statement Analysis – Financial Results
- Superior Gold Inc. (SUPGF) Income Statement Analysis – Financial Results
- Hashimoto Sogyo Holdings Co.,Ltd. (7570.T) Income Statement Analysis – Financial Results
AgeX Therapeutics, Inc. (AGE)
About AgeX Therapeutics, Inc.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 142.00K | 34.00K | 144.00K | 1.87M | 1.73M | 1.40M | 1.40M |
| Cost of Revenue | 171.00K | 13.00K | 19.00K | 158.00K | 244.00K | 364.00K | 168.00K |
| Gross Profit | -29.00K | 21.00K | 125.00K | 1.71M | 1.48M | 1.03M | 1.24M |
| Gross Profit Ratio | -20.42% | 61.76% | 86.81% | 91.54% | 85.88% | 73.93% | 88.03% |
| Research & Development | 603.00K | 1.03M | 1.46M | 4.98M | 5.90M | 6.63M | 5.78M |
| General & Administrative | 9.33M | 5.97M | 6.71M | 7.40M | 8.14M | 5.65M | 3.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.33M | 5.97M | 6.71M | 7.40M | 8.14M | 5.65M | 3.87M |
| Other Expenses | 11.00K | 13.00K | 448.00K | 44.00K | 294.00K | 183.00K | 38.00K |
| Operating Expenses | 9.93M | 7.00M | 8.16M | 12.38M | 14.04M | 12.28M | 9.65M |
| Cost & Expenses | 10.10M | 7.01M | 8.18M | 12.54M | 14.29M | 12.64M | 9.82M |
| Interest Income | 0.00 | 3.34M | 1.10M | 404.00K | 29.00K | 0.00 | 0.00 |
| Interest Expense | 4.90M | 3.34M | 1.10M | 0.00 | 0.00 | 116.00K | 0.00 |
| Depreciation & Amortization | 131.00K | 145.00K | 579.00K | 1.68M | 951.00K | 535.00K | 682.00K |
| EBITDA | -9.83M | -6.98M | -7.93M | -9.15M | -11.61M | -10.71M | -9.49M |
| EBITDA Ratio | -6,921.83% | -20,088.24% | -5,180.56% | -481.21% | -671.76% | -767.19% | -675.85% |
| Operating Income | -9.96M | -6.98M | -8.04M | -10.67M | -12.56M | -11.25M | -6.66M |
| Operating Income Ratio | -7,014.08% | -20,514.71% | -5,582.64% | -571.25% | -726.79% | -805.52% | -474.57% |
| Total Other Income/Expenses | -4.85M | -3.55M | -649.00K | 272.00K | 323.00K | 3.51M | 1.78M |
| Income Before Tax | -14.81M | -10.52M | -8.58M | -11.13M | -12.24M | -7.73M | -6.64M |
| Income Before Tax Ratio | -10,430.28% | -30,947.06% | -5,959.72% | -595.61% | -708.10% | -553.80% | -472.72% |
| Income Tax Expense | -8.00K | 152.00K | 1.64M | -150.00K | 148.00K | 3.51M | -1.80M |
| Net Income | -14.80M | -10.67M | -10.22M | -10.98M | -12.38M | -7.50M | -6.58M |
| Net Income Ratio | -10,424.65% | -31,394.12% | -7,097.22% | -587.58% | -716.67% | -537.39% | -468.66% |
| EPS | -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| EPS Diluted | -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| Weighted Avg Shares Out | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M |
| Weighted Avg Shares Out (Dil) | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M |
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
AgeX Therapeutics Reports Second Quarter 2023 Financial Results
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock
AgeX Therapeutics Announces Appeal of NYSE American Determination
DEINOVE – Adoption of the resolutions at the Shareholders’ Extraordinary General Meeting on October 17, 2022
Academy of Greatness & Excellence Acquires Former Neumann Prep High School Property
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
AgeX Therapeutics: New LyGenesis Merger May Unlock Much-Needed Value
Source: https://incomestatements.info
Category: Stock Reports